Switch theme
Sign up to access all valuation multiples
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
2006
n/a
LTM Revenue $599M
LTM EBITDA $298M
$16.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sichuan Biokin has a last 12-month revenue (LTM) of $599M and a last 12-month EBITDA of $298M.
In the most recent fiscal year, Sichuan Biokin achieved revenue of $808M and an EBITDA of $569M.
Sichuan Biokin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sichuan Biokin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $599M | XXX | $808M | XXX | XXX | XXX |
| Gross Profit | $566M | XXX | $771M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $298M | XXX | $569M | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 70% | XXX | XXX | XXX |
| EBIT | $320M | XXX | $520M | XXX | XXX | XXX |
| EBIT Margin | 53% | XXX | 64% | XXX | XXX | XXX |
| Net Profit | $296M | XXX | $515M | XXX | XXX | XXX |
| Net Margin | 49% | XXX | 64% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sichuan Biokin's stock price is CNY 301 (or $42).
Sichuan Biokin has current market cap of CNY 121B (or $16.8B), and EV of CNY 120B (or $16.6B).
See Sichuan Biokin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.6B | $16.8B | XXX | XXX | XXX | XXX | $0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sichuan Biokin has market cap of $16.8B and EV of $16.6B.
Sichuan Biokin's trades at 20.6x EV/Revenue multiple, and 29.3x EV/EBITDA.
Equity research analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sichuan Biokin has a P/E ratio of 56.6x.
See valuation multiples for Sichuan Biokin and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.8B | XXX | $16.8B | XXX | XXX | XXX |
| EV (current) | $16.6B | XXX | $16.6B | XXX | XXX | XXX |
| EV/Revenue | 27.8x | XXX | 20.6x | XXX | XXX | XXX |
| EV/EBITDA | 55.9x | XXX | 29.3x | XXX | XXX | XXX |
| EV/EBIT | 52.1x | XXX | 32.0x | XXX | XXX | XXX |
| EV/Gross Profit | 29.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 56.6x | XXX | 32.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 30.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSichuan Biokin's last 12 month revenue growth is -49%
Sichuan Biokin's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sichuan Biokin's rule of 40 is -170% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sichuan Biokin's rule of X is -72% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sichuan Biokin and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -49% | XXX | -38% | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 70% | XXX | XXX | XXX |
| EBITDA Growth | -112% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -170% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -72% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sichuan Biokin acquired XXX companies to date.
Last acquisition by Sichuan Biokin was XXXXXXXX, XXXXX XXXXX XXXXXX . Sichuan Biokin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sichuan Biokin founded? | Sichuan Biokin was founded in 2006. |
| Where is Sichuan Biokin headquartered? | Sichuan Biokin is headquartered in China. |
| Is Sichuan Biokin publicy listed? | Yes, Sichuan Biokin is a public company listed on SHG. |
| What is the stock symbol of Sichuan Biokin? | Sichuan Biokin trades under 688506 ticker. |
| When did Sichuan Biokin go public? | Sichuan Biokin went public in 2023. |
| Who are competitors of Sichuan Biokin? | Similar companies to Sichuan Biokin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sichuan Biokin? | Sichuan Biokin's current market cap is $16.8B |
| What is the current revenue of Sichuan Biokin? | Sichuan Biokin's last 12 months revenue is $599M. |
| What is the current revenue growth of Sichuan Biokin? | Sichuan Biokin revenue growth (NTM/LTM) is -49%. |
| What is the current EV/Revenue multiple of Sichuan Biokin? | Current revenue multiple of Sichuan Biokin is 27.8x. |
| Is Sichuan Biokin profitable? | Yes, Sichuan Biokin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sichuan Biokin? | Sichuan Biokin's last 12 months EBITDA is $298M. |
| What is Sichuan Biokin's EBITDA margin? | Sichuan Biokin's last 12 months EBITDA margin is 50%. |
| What is the current EV/EBITDA multiple of Sichuan Biokin? | Current EBITDA multiple of Sichuan Biokin is 55.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
